Clinical Trials Logo

Clinical Trial Summary

Tranexamic acid has been proposed and used for prevention and management of antepartum and postpartum hemorrhage.


Clinical Trial Description

Bleeding during pregnancy is associated with a three- to fourfold increase in perinatal mortality. Hemorrhage in pregnancy is characterized by activation of the fibrinolytic system. Tranexamic acid is a potent pharmaceutical agent that suppresses fibrinolysis, and thus can be used for managing hemorrhage in pregnancy. The FDA's pregnancy category for tranexamic acid is category B. Tranexamic acid has been used to decrease blood loss and treatment of intra partum blood loss in cesarean section also it has been used for prevention and management of postpartum hemorrhage after vaginal bleeding, regardless of whether the bleeding is due to genital tract trauma or other causes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03632824
Study type Interventional
Source Hawler Medical University
Contact
Status Completed
Phase N/A
Start date February 1, 2016
Completion date January 18, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02363569 - The Prognosis of Early Pregnancy With Post Coital Bleeding N/A